Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 170.80
Change Today +11.70 / 7.35%
Volume 239.2K
As of 8:10 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

kitov pharmaceuticals holdin (KTOV) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/21/14 - $686.40
52 Week Low
03/31/15 - $123.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

kitov pharmaceuticals holdin (KTOV) Related Businessweek News

No Related Businessweek News Found

kitov pharmaceuticals holdin (KTOV) Details

Kitov Pharmaceuticals Holdings Ltd. engages in the development of combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems. The company is developing KIT-301 and KIT-302 for the treatment of osteoarthritis. The company was formerly known as Mainrom Line Logistics Ltd. and changed its name to Kitov Pharmaceuticals Holdings Ltd. in August 2013. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel.

kitov pharmaceuticals holdin (KTOV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kitov pharmaceuticals holdin (KTOV) Key Developments

Kitov Pharmaceuticals Holdings LTD Auditor Raises 'Going Concern' Doubt

Kitov Pharmaceuticals Holdings LTD filed its Annual on Mar 18, 2015 for the period ending Dec 31, 2014. In this report its auditor, Somekh Chaikin, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Kitov Pharmaceuticals Holdings LTD, Special/Extraordinary Shareholders Meeting, Nov 20, 2014

Kitov Pharmaceuticals Holdings LTD, Special/Extraordinary Shareholders Meeting, Nov 20, 2014., at 08:30 Israel Standard Time.

Kitov Pharmaceutical Holdings Ltd. Signs Strategic Cooperation Agreement with Dexcel Pharma Ltd

Kitov Pharmaceutical Holdings Ltd. has signed a strategic cooperation agreement with Dexcel Pharma Ltd. to develop and produce its treatment for hypertension, KIT-302. Kitov is preparing a Phase III clinical trial of the drug. Dexcel will develop drug's final formulation for the filing of a New Drug Application with the US Food and Drug Administration. Kitov will pay Dexcel $2 million in cash and $1.5 million in shares to use the company's facilities. Dexcel will pay Kitov $500,000 in two equal installments, and will have the first right in global marketing negotiations and commercial production of KIT-302.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KTOV:IT 170.80 +11.70

KTOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KTOV.
View Industry Companies

Industry Analysis


Industry Average

Valuation KTOV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITOV PHARMACEUTICALS HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at